Panel Discussion | Our Understanding on the Pathophysiology and Mechanism of Atherosclerosis and the New Therapeutic Options

Sunday, March 9, 2025

9:11 AM – 9:35 AM ET

Panel Moderator(s)

Takashi Akasaka, MD, PhD

Senior Consultant
Nishinomiya Watanabe Cardiovascular Cerebral Center
Nishinomiya, Hyogo, Japan

Disclosure(s): Daiichi Sankyo: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Nipro Co.: Consulting Fees (e.g., advisory boards) (Ongoing); Otsuka Pharmaceuticals: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, December 5, 2024); Terumo Corporation: Employee (Ongoing)
Allen J. Taylor, MD

Chairman of Cardiology
MedStar Heart and Vascular Institute
Washington, District of Columbia, United States

Disclosure(s): Amgen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Heartflow, Inc: Consultant (Ongoing)
Renu Virmani, MD

President
CVPath Institute, Inc.
Gaithersburg, Maryland, United States

Disclosure(s): Amplitude Vascular Systems: Grant/Research Support (Ongoing); BD: Grant/Research Support (Ongoing); celenova: Grant/Research Support (Ongoing); Concept Medical: Grant/Research Support (Ongoing); Edward Lifesciences: Grant/Research Support (Ongoing); Imperative Care: Grant/Research Support (Ongoing); Recor Medical, Inc.: Grant/Research Support (Ongoing); Reflow Medical: Grant/Research Support (Ongoing); the jacobs institute: Grant/Research Support (Ongoing); Vascudyne: Grant/Research Support (Ongoing); Xeltis: Grant/Research Support (Ongoing)

Panel Discussant(s)

Paul T. Campbell, MD

Interventional Cardiologist
Sanger Heart & Vascular Institute
Concord , North Carolina, United States

Disclosure(s): No financial relationships to disclose
Charles German, MD, MS, FAHA, FASPC

Assistant Professor
Georgetown University

Disclosure(s): No financial relationships to disclose
Ramzi Khamis, MB ChB PhD FRCP FESC

Consultant Cardiologist. Clinical Director of Cardiology and Cardiothoracic Surgery
Imperial College London and Imperial College Healthcare NHS Trust
London , England, United Kingdom

Disclosure(s): No financial relationships to disclose
Peter Libby, MD

Cardiovascular Specialist
Brigham and Women's Hospital
Boston, Massachusetts, United States

Disclosure(s): Amgen: Consultant (Ongoing), Scientific Advisory Board (Ongoing); Baim Institute: Consultant (Ongoing); Beren Therapeutics: Consultant (Ongoing); Caristo Diagnostics: Scientific Advisory Board (Ongoing); CSL Behring: Scientific Advisory Board (Ongoing); Elucid Bioimaging: Scientific Advisory Board (Ongoing); Esperion Therapeutics: Consultant (Ongoing); Genentech: Consultant (Ongoing), Grant/Research Support (Ongoing); Kancera: Consultant (Ongoing), Scientific Advisory Board (Ongoing); Kowa Pharmaceuticals: Consultant (Ongoing), Scientific Advisory Board (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Scientific Advisory Board (Ongoing); Novo Nordisk: Consultant (Ongoing), Grant/Research Support (Ongoing); Olatec Therapeutics: Scientific Advisory Board (Ongoing); PlaqueTec Ltd: Scientific Advisory Board (Ongoing); Polygon Therapeutics: Scientific Advisory Board (Ongoing); Sanofi-Regeneron: Consultant (Ongoing); Soley Thereapeutics: Financial Interest (Ongoing); TenSixteen Bio: Financial Interest (Ongoing); XBiotech, Inc.: Board of Directors (Ongoing), Employee (Ongoing)
Seth S. Martin, MD, MHS, FACC, FAHA, FASPC

Professor
Johns Hopkins
Reisterstown, Maryland, United States

Disclosure(s): Amgen: Consulting Fees (e.g., advisory boards) (Ongoing); Arrowhead: Consulting Fees (e.g., advisory boards) (Ongoing); Corrie Health: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Heartflow, Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Ongoing); New Amsterdam Pharma: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing); Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing)
Nehal N. Mehta, MD, MSCE

Clinical Professor of Medicine
The George Washington University
Washington, District of Columbia, United States

Disclosure(s): No financial relationships to disclose
Pedro R. Moreno, MD, FACC

Director - Quality Assurance for Cardiology
Mount Sinai Hospital
New York, New York, United States

Disclosure information not submitted.
Robert S. Rosenson, MD

Director of Metabolism and Lipids
Mount Sinai Health System
New York, New York, United States

Disclosure(s): Amgen Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Arrowhead Pharmaceuticals, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Avilar Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); CRISPR Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Editas Medicine: Consulting Fees (e.g., advisory boards) (Ongoing); Eli Lilly and Company: Consulting Fees (e.g., advisory boards) (Ongoing); GSK: Consulting Fees (e.g., advisory boards) (Ongoing); Intercept Pharmaceuticals Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Kowa American Corporation: Non-promotional lecture (Ongoing); Life Extension: Consulting Fees (e.g., advisory boards) (Ongoing); Lipigon Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); MediMergent LLC: Stock-privately held company (Ongoing); New Amsterdam: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing); Organon: Consulting Fees (e.g., advisory boards) (Ongoing); Precision BioSciences: Consulting Fees (e.g., advisory boards) (Ongoing); Regeneron Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Rona Therapeutics, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Ultragenyx Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Verve: Consulting Fees (e.g., advisory boards) (Ongoing); Viatris: Non-promotional lecture (Ongoing); William Blair: Consulting Fees (e.g., advisory boards) (Ongoing); Wolters Kluwer: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Habib Samady, MD, FACC, FSCAI

Adjunct Professor, Emory University
Emory University
Atlanta, Georgia, United States

Disclosure(s): Covanos Inc.: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Disclosure(s):

Takashi Akasaka, MD, PhD: Daiichi Sankyo: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Nipro Co.: Consulting Fees (e.g., advisory boards) (Ongoing); Otsuka Pharmaceuticals: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, December 5, 2024); Terumo Corporation: Employee (Ongoing)

Allen J. Taylor, MD: Amgen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Heartflow, Inc: Consultant (Ongoing)

Renu Virmani, MD: Amplitude Vascular Systems: Grant/Research Support (Ongoing); BD: Grant/Research Support (Ongoing); celenova: Grant/Research Support (Ongoing); Concept Medical: Grant/Research Support (Ongoing); Edward Lifesciences: Grant/Research Support (Ongoing); Imperative Care: Grant/Research Support (Ongoing); Recor Medical, Inc.: Grant/Research Support (Ongoing); Reflow Medical: Grant/Research Support (Ongoing); the jacobs institute: Grant/Research Support (Ongoing); Vascudyne: Grant/Research Support (Ongoing); Xeltis: Grant/Research Support (Ongoing)

Paul T. Campbell, MD: No financial relationships to disclose

Charles German, MD, MS, FAHA, FASPC: No financial relationships to disclose

Ramzi Khamis, MD PhD: No financial relationships to disclose

Peter Libby, MD: Amgen: Consultant (Ongoing), Scientific Advisory Board (Ongoing); Baim Institute: Consultant (Ongoing); Beren Therapeutics: Consultant (Ongoing); Caristo Diagnostics: Scientific Advisory Board (Ongoing); CSL Behring: Scientific Advisory Board (Ongoing); Elucid Bioimaging: Scientific Advisory Board (Ongoing); Esperion Therapeutics: Consultant (Ongoing); Genentech: Consultant (Ongoing), Grant/Research Support (Ongoing); Kancera: Consultant (Ongoing), Scientific Advisory Board (Ongoing); Kowa Pharmaceuticals: Consultant (Ongoing), Scientific Advisory Board (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Scientific Advisory Board (Ongoing); Novo Nordisk: Consultant (Ongoing), Grant/Research Support (Ongoing); Olatec Therapeutics: Scientific Advisory Board (Ongoing); PlaqueTec Ltd: Scientific Advisory Board (Ongoing); Polygon Therapeutics: Scientific Advisory Board (Ongoing); Sanofi-Regeneron: Consultant (Ongoing); Soley Thereapeutics: Financial Interest (Ongoing); TenSixteen Bio: Financial Interest (Ongoing); XBiotech, Inc.: Board of Directors (Ongoing), Employee (Ongoing)

Seth S. Martin, MD, MHS, FACC, FAHA, FASPC: Amgen: Consulting Fees (e.g., advisory boards) (Ongoing); Arrowhead: Consulting Fees (e.g., advisory boards) (Ongoing); Corrie Health: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Heartflow, Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Ongoing); New Amsterdam Pharma: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing); Verve Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing)

Nehal N. Mehta, MD, MSCE: No financial relationships to disclose

Robert S. Rosenson, MD: Amgen Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Arrowhead Pharmaceuticals, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Avilar Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); CRISPR Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Editas Medicine: Consulting Fees (e.g., advisory boards) (Ongoing); Eli Lilly and Company: Consulting Fees (e.g., advisory boards) (Ongoing); GSK: Consulting Fees (e.g., advisory boards) (Ongoing); Intercept Pharmaceuticals Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Kowa American Corporation: Non-promotional lecture (Ongoing); Life Extension: Consulting Fees (e.g., advisory boards) (Ongoing); Lipigon Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); MediMergent LLC: Stock-privately held company (Ongoing); New Amsterdam: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis: Consulting Fees (e.g., advisory boards) (Ongoing); Organon: Consulting Fees (e.g., advisory boards) (Ongoing); Precision BioSciences: Consulting Fees (e.g., advisory boards) (Ongoing); Regeneron Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Rona Therapeutics, Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Ultragenyx Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing); Verve: Consulting Fees (e.g., advisory boards) (Ongoing); Viatris: Non-promotional lecture (Ongoing); William Blair: Consulting Fees (e.g., advisory boards) (Ongoing); Wolters Kluwer: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Habib Samady, MD, FACC, FSCAI: Covanos Inc.: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)